Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816659 · ClinicalTrials.gov registry record · Phase 1
An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01816659: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01816659 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01816659, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn more about the possible effects of metformin extended release (ER) in patients with colon cancer or adenomas who are about to have surgery. The safety of this drug will also be studied. Metformin-ER is commonly used to control blood sugar levels in patients with diabetes. It is also designed to block a protein in tumor cells that is important in tumor growth and blood vessel development. This may cause cell death or reduce the spread of the disease.
Interventions
- DRUG Metformin ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816659
The ClinicalTrials.gov registry entry for NCT01816659 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin ER is the first listed.
NCT01816659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01816659 about?
NCT01816659 is a clinical study titled "An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin". The goal of this clinical research study is to learn more about the possible effects of metformin extended release (ER) in patients with colon cancer or adenomas who are about to have surgery. The safety of this drug will also be studied. Metformin-ER is commonly used to control blood sugar levels ...
What is the current status of trial NCT01816659?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01816659?
The interventions under investigation include: Metformin ER (DRUG).
Who is sponsoring clinical trial NCT01816659?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.